- 2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel)
- Adding Pembrolizumab to Chemotherapy Improves Survival in People With Advanced Cervical Cancer
- AffyImmune Therapeutics Announces Positive Safety and Early Efficacy Results from Phase 1 Study of AIC100 CAR T Cells in Anaplastic and Advanced Thyroid Cancers
- Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors
- Artiva Biotherapeutics Presents Initial Data from First-in-Human Phase 1/2 Clinical Trial of AB-101
- AstraZeneca to highlight momentum of cancer medicines across its pipeline
- Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in R/R CLL
- Daiichi Sankyo Showcases Latest Research Towards Creating New Standards of Care for Patients with Cancer
- Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline
- EMD Serono Highlights Commitment to Improving Cancer Outcomes
- Fianlimab Combined with Libtayo Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
- Genmab Announces Multiple Abstracts to be Presented
- Gilead And Kite Oncology To Showcase Advances Across The Pipeline Aiming To Address Unmet Needs In Cancer Care
- Immutep Announces Publication of Abstracts
- Karyopharm to Present New Selinexor Data
- KEYTRUDA + LENVIMA Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as 1L Treatment for Patients With Advanced Renal Cell Carcinoma
- Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma
- Merck to Present New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology
- Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402
- Takeda to Present Oncology Portfolio and Pipeline Data
Menu
